South Africa is preparing to roll out one of the most significant advances in HIV prevention in recent years, with President Cyril Ramaphosa set to officially launch the long-acting HIV prevention injection Lenacapavir.
The launch, taking place in Secunda, Mpumalanga, marks a new phase in the country’s efforts to reduce new HIV infections and strengthen prevention strategies alongside its extensive treatment programme.
Health experts have described Lenacapavir as a potentially transformative tool in the global fight against HIV due to its ability to provide long-term protection with only two injections per year.
New prevention option could improve access and adherence
South Africa has the world’s largest HIV treatment programme, with millions of people receiving antiretroviral therapy. However, public health officials have consistently stressed that preventing new infections remains essential if the country is to ultimately end the epidemic.
Unlike traditional pre-exposure prophylaxis (PrEP) medication, which requires daily use, Lenacapavir is administered once every six months.
Health authorities believe the longer dosing interval could help address one of the biggest challenges in HIV prevention: maintaining consistent adherence to medication.
The national launch will be attended by President Ramaphosa, Health Minister Aaron Motsoaledi, Mpumalanga Premier Mandla Ndlovu, civil society organisations and international health partners, including The Global Fund.
Government officials have described the rollout as a key step in South Africa’s broader strategy to eliminate HIV as a public health threat in the coming years.
Health Minister addresses safety concerns
As public interest in the new injection grows, questions regarding safety and potential side effects have also emerged.
Speaking in Parliament, Health Minister Aaron Motsoaledi sought to reassure lawmakers and the public that Lenacapavir does not cause HIV, cancer or any other known disease.
The minister explained that, like most medications, the injection may produce mild side effects in some individuals, including nausea. However, he said serious adverse reactions remain uncommon.
Motsoaledi’s remarks followed questions raised by members of the National Assembly regarding the safety profile of the medication.
The minister also revealed that public demand for the injection has been stronger than anticipated since its introduction in Mpumalanga.
According to figures provided by the Department of Health, the province initially received 1,800 doses of Lenacapavir. Within a short period, approximately 400 doses had already been administered.
Motsoaledi said members of the public had actively sought out the new prevention option, with many people reportedly queuing to receive the injection.
Health officials believe the early response demonstrates strong public interest in more convenient HIV prevention methods and could help accelerate efforts to reduce new infections across South Africa.
As the rollout expands, Lenacapavir is expected to become an important component of the country’s HIV prevention programme, complementing existing treatment and prevention services.
Source: Department of Health, Parliament of South Africa